BioMarin Pharmaceutical (NASDAQ:BMRN) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, April 25th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.
BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, February 22nd. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.06). BioMarin Pharmaceutical had a negative return on equity of 3.18% and a negative net margin of 8.91%. The company had revenue of $358.31 million during the quarter, compared to analyst estimates of $346.24 million. On average, analysts expect BioMarin Pharmaceutical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of BMRN opened at $84.42 on Thursday. BioMarin Pharmaceutical has a 52-week low of $75.81 and a 52-week high of $100.51. The firm has a market capitalization of $14,869.30, a price-to-earnings ratio of -126.00 and a beta of 1.69. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.70 and a quick ratio of 2.12.
BMRN has been the subject of a number of recent research reports. JPMorgan Chase cut their target price on BioMarin Pharmaceutical from $131.00 to $129.00 and set an “outperform” rating for the company in a research note on Wednesday, January 24th. BidaskClub downgraded BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a research note on Saturday, January 20th. Zacks Investment Research raised BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and set a $101.00 price objective for the company in a research report on Tuesday, January 16th. Royal Bank of Canada reissued a “hold” rating and set a $94.00 price objective on shares of BioMarin Pharmaceutical in a research report on Tuesday, February 27th. Finally, Morgan Stanley cut their price objective on BioMarin Pharmaceutical from $115.00 to $112.00 and set an “overweight” rating for the company in a research report on Friday, February 23rd. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $112.34.
COPYRIGHT VIOLATION WARNING: This news story was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://stocknewstimes.com/2018/04/19/biomarin-pharmaceutical-bmrn-set-to-announce-quarterly-earnings-on-wednesday.html.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.